SARS-CoV-2 vaccines breakthrough infection hospitalizations after one dose in Libya: cohort study
| Autor: | Badereddin B Annajar, Iman Amin Al msellati, Alaa Hadi Abdelhamid, Mohammed Eltikar, Hafsa alemam, Mohamed Hadi Mohamed Abdelhamid |
|---|---|
| Přispěvatelé: | Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, National Center for Disease Control |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0303 health sciences
Pediatrics medicine.medical_specialty Virus transmission business.industry Mortality rate Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viruses virus diseases Breakthrough infection medicine.disease_cause 3. Good health Vaccination 03 medical and health sciences 0302 clinical medicine [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases Pandemic Medicine 030212 general & internal medicine business skin and connective tissue diseases 030304 developmental biology Cohort study Coronavirus |
| Popis: | SARS-CoV-2 infection is widely spread over people, from youth to the elderly. Vaccination against SARS-CoV-2 is an important preventive measurement to help end the SARS-CoV-2 pandemic. From 30 April to 15 July, we collected the number of people infected with SARS-COV-2 and the mortality rate from daily reports issued by the National Center for Disease Control of Libya (NCDC). Approximately 445000 doses have been administered in Libya since 10 April, and 5 thousand doses are now being administered during this period on a daily basis. To estimate the rate of breakthrough vaccine infection of the SARS-COV-2 in Libya. We found that one dose of the three different types of vaccines had decreased the virus transmission across people and mortality rate until 10 weeks after the first dose. This study highlights the dramatic success of the early months of the nation’s coronavirus vaccines rollout. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|